Ainos Inc Stock Price, News & Analysis

Ainos (NASDAQ: AIMD) has reported promising interim results from its veterinary clinical trial of VELDONA, a low-dose interferon therapy for Feline Chronic Gingivostomatitis (FCGS). The trial, involving 30 cats, shows significant improvements in treating chronic inflammation. Key findings from the first three completed cases include inflammation score reductions ranging from 10.5% to 44.4%, with successful reduction or elimination of steroid dependency. The therapy demonstrated strong tolerability with no significant side effects. This breakthrough positions Ainos to tap into the global pet dental market, projected to reach $13 billion by 2030. The results suggest VELDONA could revolutionize companion animal immunotherapy by offering a steroid-free treatment option for chronic inflammatory conditions.

Ainos (NASDAQ:AIMD) has achieved significant commercial progress with its AI-powered scent digitization platform, AI Nose, as highlighted in a Water Tower Research report. The company reported a 412% year-over-year revenue growth, primarily driven by AI Nose sales in Japan's elderly care market through its partnership with Nisshinbo Micro Devices Inc.

The company reached a key milestone with over 80% accuracy in detecting bowel movements in elderly patients through its AI Nose technology. This achievement is particularly significant for Japan's aging healthcare market, which faces a projected shortage of 570,000 caregivers by 2040.

Ainos has expanded AI Nose applications beyond healthcare into robotics and industrial sectors. Notable developments include successful integration with ugo's service robots and a partnership with a major semiconductor company for smart factory applications across 46 facilities.

Ainos (NASDAQ:AIMD) reported strong Q1 2025 financial results, with revenue surging 412% year-over-year to $106,207, primarily driven by AI Nose product sales. The company achieved a significant turnaround from a gross loss to a gross profit of $87,974. Ainos's AI Nose technology, initially focused on healthcare, is expanding into robotics and industrial sectors through strategic partnerships with ugo Inc. (Japanese robotics leader) and Advanced Semiconductor Engineering (semiconductor packaging giant). The company also advanced its VELDONA® therapeutic program, securing TFDA approval for HIV oral warts trials and IRB clearance for Sjögren's syndrome trials in Taiwan. The electronic nose market is projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032, positioning Ainos to capitalize on the expanding AI and robotics sectors.

Ainos (NASDAQ: AIMD) has formed a strategic partnership with ASE Chung Li (ASECL), a key semiconductor manufacturing site of Advanced Semiconductor Engineering, to implement AI-driven scent digitization in smart manufacturing.

Through a binding MOU, the partnership focuses on optimizing and deploying AI Nose technology in ASECL's operations. The technology transforms volatile organic compounds (VOCs) patterns into real-time "Smell ID" data, offering a new dimension in semiconductor manufacturing intelligence.

Key benefits of AI Nose implementation include:

• Real-time air quality monitoring for worker safety
• AI-driven predictive maintenance and energy efficiency
• Precision process control and yield optimization
• Enhanced ESG compliance and sustainable manufacturing

This collaboration aims to address the untapped potential of airborne VOCs in semiconductor fabs, which can impact yield, equipment health, and worker safety.

Ainos (NASDAQ:AIMD) has successfully integrated its AI Nose technology into a humanoid robot developed by ugo, Japan's leading service robot company, according to a new Water Tower Research report. The integration was completed within weeks of announcing the partnership, marking a global first in robotic smell detection.

The project is now entering the software integration phase, with backend control system and user interface design expected to complete in 2-4 weeks. Field testing will follow in various environments including office buildings, data centers, manufacturing plants, and public facilities.

The partnership targets Japan's robust robotics market, which produced 38% of global robots in 2023 and has a projected service robot market of $1.2 billion in 2025. The global service robotics market is estimated at $40.6 billion. Ainos plans a pilot launch in 2025 followed by commercial rollout in 2026, utilizing a subscription-based revenue model.

Ainos (NASDAQ:AIMD) has achieved a groundbreaking milestone by successfully installing its AI Nose olfaction module on a humanoid robot developed by ugo, Japan's leading service robotics company, marking the world's first robot with a functional sense of smell.

The installation, completed on April 9, 2025, integrates Ainos' proprietary system combining gas sensor arrays, real-time processing, and AI algorithms to digitize and identify volatile organic compounds into 'Smell IDs'. This technology enables robots to detect odors and environmental conditions similar to human olfaction.

Following the installation, the companies will proceed with software integration and real-world training, expected to complete within 2-4 weeks. The system will then undergo deployment tests in commercial buildings and public spaces, focusing on odor detection, safety alerts, and data collection for AI model training.

Applications include:

• Smart manufacturing for gas leak and chemical anomaly detection
• Workplace safety monitoring
• Healthcare and elderly care surveillance
• Consumer applications in smart homes and food freshness

Ainos (NASDAQ:AIMD) has achieved significant milestones in advancing its VELDONA® oral interferon drug platform. The company secured TFDA approval for HIV-related oral warts clinical trial and IRB clearance for Sjögren's Syndrome study in Taiwan.

The HIV oral warts trial (Protocol ID: 03HUHI19) will commence in June 2025 at National Taiwan University Hospital, targeting completion in 2H 2026. The global market for HIV-related HPV manifestations is estimated at $500-700 million.

The Sjögren's Syndrome trial (Protocol ID: 24PSS01) received IRB approval from Taipei Medical University, with TFDA clearance expected in August 2025. The trial aims to evaluate VELDONA's efficacy in improving salivary flow and alleviating dryness symptoms, targeting completion in 1H 2027. The global Sjögren's Syndrome therapeutics market is projected to reach $3.3 billion by 2030.

Ainos (NASDAQ:AIMD) is expanding its AI Nose technology from healthcare into robotics and semiconductor manufacturing, according to a new Water Tower Research report. The company's proprietary technology digitizes scent into Smell IDs using MEMS sensors and AI models, achieving nearly 80% accuracy across 22 VOC types in semiconductor settings and over 90% accuracy in women's health applications.

The company has secured strategic partnerships in Japan with a service robot company for integration into robots operating in office buildings, data centers, and public infrastructure. Additionally, Ainos is collaborating with the world's largest semiconductor packaging and testing company for smart factory initiatives.

The company's execution timeline includes: mass production of elderly care products in 1H 2025, pilot deployment in robotics and semiconductor factories in 2H 2025, and industrial projects scaling commercially in 2026. These initiatives target the e-nose market, projected to reach $76.5B by 2032, and the robotics market, expected to reach $178.6B by 2030.

Ainos (NASDAQ:AIMD), a pioneer in AI-powered scent digitization, has announced its participation in an upcoming fireside chat with Water Tower Research (WTR) scheduled for April 8, 2025, at 10:00 a.m. ET.

The discussion will feature WTR's senior research analyst Do Kim and managing director John Roy. During the session, Ainos will explore various aspects of their AI Nose technology, including:

• Applications in smart manufacturing and robotics
• Impact of AI-driven digitized smell beyond healthcare
• Recent collaboration programs in robotic and semiconductor manufacturing
• Technological advancements in training AI's digital olfaction
• Market opportunities across different industries

The event will be listen-only, with a replay available on Ainos' investor relations website.